Natsuko Chiba

The BRCA1 and BARD1 association with the RNA polymerase II holoenzyme.

Expression of an amino-terminal BRCA1 deletion mutant causes a dominant growth inhibition in MCF10A cells.

BRCA1/BARD1 ubiquitinate phosphorylated RNA polymerase II.

[The state of the art of hereditary cancer studies].

[Retrospective analysis on efficacy and toxicity of 5-fluorouracil (5-FU) and l-leucovorin (l-LV) in advanced or recurrent colorectal cancer].

AFP-producing hepatoid adenocarcinoma in association with Barrett's esophagus with multiple liver metastasis responding to paclitaxel/CDDP: a case report.

[A case of malignant melanoma from the esophagus responding to weekly paclitaxel therapy].

Dose escalation study of docetaxel and nedaplatin in patients with relapsed or refractory squamous cell carcinoma of the esophagus pretreated using cisplatin, 5-fluorouracil, and radiation.

[Familial breast cancer genes].

[Clinical characteristics of cancer of unknown primary (CUP)--a summary of 22 cases].

Rapid recruitment of BRCA1 to DNA double-strand breaks is dependent on its association with Ku80.

Identification of breast tumor mutations in BRCA1 that abolish its function in homologous DNA recombination.

BRCA1 contributes to transcription-coupled repair of DNA damage through polyubiquitination and degradation of Cockayne syndrome B protein.

Octa-arginine mediated delivery of wild-type Lnk protein inhibits TPO-induced M-MOK megakaryoblastic leukemic cell growth by promoting apoptosis.